Phreesia (PHR) Insider Smith Mark Douglas Buys $185K of Stock

Smith Mark Douglas Adds to Phreesia, Inc. Stock Holdings

Smith Mark Douglas acquired 19,290 shares of Phreesia, Inc. NYSE:PHR on June 24, 2026. The shares were purchased at an average price of $9.59 each, bringing the total value of the transaction to $184,991.10. This filing with the Securities and Exchange Commission shows the purchase was made directly on the open market without a pre-arranged trading plan.

Synchronized Insider Purchases Across the Board

The purchase by Smith Mark Douglas was part of a broader wave of identical transactions executed on the exact same day. Five other insiders—Jon Kessler, Gillian Munson, Lisa Egbuonu-Davis, Ramin Sayar, and Lainie Goldstein—each picked up the exact same block of 19,290 shares at the identical price of $9.59 per share, totaling $184,991.10 per person. Such coordinated activity among multiple key individuals provides a window into how leadership views the company's valuation following recent market adjustments.

Phreesia Stock Performance and Recent Trading

Phreesia shares have experienced downward pressure recently, trading near the lower end of their 52-week range between $7.77 and $25.00. The stock changes hands below its 50-day moving average of $11.15 and its 200-day moving average of $11.81. With a market capitalization of roughly $622.6 million, the healthcare software provider carries a forward price-to-earnings ratio of 6.24, reflecting expectations for future profitability.

Wall Street Analyst Updates and Price Targets

Equity research firms have actively adjusted their outlooks on Phreesia over recent months. On October 12, 2026, Barclays maintained its equal-weight rating while lifting its target to $11.00 from $10.00. Earlier in September, Raymond James issued a downgrade to a market perform rating, while DA Davidson kept its buy rating with a $13.00 target. Baird maintained a neutral stance with an $11.00 target, Freedom Capital Markets kept a buy rating with a $14.00 target, and RBC Capital reiterated an outperform rating with a $19.00 target. Wells Fargo adjusted its equal-weight rating with a $10.00 target, and Canaccord Genuity maintained a buy rating with a $16.00 target. Across the Street, the company holds a consensus buy recommendation and a mean price target of $13.94.

About Phreesia, Inc.

Phreesia, Inc. builds software and payment solutions designed for healthcare organizations in the United States and Canada. Its platform handles patient intake, appointment scheduling, digital check-ins, and secure payment processing through automated workflows and mobile tools. Hospitals, ambulatory practices, and life sciences companies use these systems to streamline operations and manage patient communication.

What to Watch Next for Phreesia

Investors are keeping an eye on the company's financial trajectory as the next earnings report is scheduled for December 7, 2026. These insider transactions offer a retrospective look at internal sentiment, though they do not guarantee future stock movements or operational results.